Bromocriptine-13C-d3
(Synonyms: CB-154-13C-d3) 目录号 : GC46954
A neuropeptide with diverse biological activities
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Bromocriptine-13C-d3 is intended for use as an internal standard for the quantification of bromocriptine by GC- or LC-MS. Bromocriptine is a dopamine receptor agonist (Kis = 1,659, 12.2, 12.2, 59.7, and 1,691 nM for dopamine D1, D2, D3, D4, and D5 receptors, respectively).1 It also binds to the serotonin (5-HT) receptor subtypes 5-HT1A and 5-HT1D (Kis = 12.9 and 10.7 nM, respectively), as well as α1-adrenergic receptors (Kis = 1.12-4.17 nM).1,2 Bromocriptine (5 mg/kg) restores locomotor activity, without inducing dyskinesia, in a macaque model of Parkinson's disease induced by MPTP.3 Formulations containing bromocriptine have been used in the treatment of Parkinson's disease, hyperprolactinemia-associated dysfunctions, and acromegaly.
1.Kvernmo, T., HÄrtter, S., and BÜrger, E.A review of the receptor-binding and pharmacokinetic properties of dopamine agonistsClin. Ther.28(8)1065-1078(2006) 2.Millan, M.J., Maiofiss, L., Cussac, D., et al.Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypesJ. Pharmacol. Exp. Ther.303(2)791-804(2002) 3.Rouillard, C., BÉdard, P.J., and De Paolo, T.Effects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF 38393Eur. J. Pharmacol.185(2-3)209-215(1990)
| Cas No. | N/A | SDF | |
| 别名 | CB-154-13C-d3 | ||
| Canonical SMILES | O[C@@]([C@@](CCC1)([H])N1C2=O)(O[C@@]3(C(C)C)NC([C@@H](CN([13C]([2H])([2H])[2H])[C@]4([H])C5)C=C4C6=C7C5=C(Br)NC7=CC=C6)=O)N([C@H]2CC(C)C)C3=O | ||
| 分子式 | C31[13C]H37D3BrN5O5 | 分子量 | 658.6 |
| 溶解度 | Chloroform: soluble | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.5184 mL | 7.5919 mL | 15.1837 mL |
| 5 mM | 0.3037 mL | 1.5184 mL | 3.0367 mL |
| 10 mM | 0.1518 mL | 0.7592 mL | 1.5184 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。